CD24 and colorectal carcinoma: Afatinib’s documented capacity to inhibit senescent cell proliferation and induce apoptosis provides a compelling mechanistic rationale for its application in targeting CSS-related pathways, particularly given our novel finding linking CD24 to senescence induction in CRC.